Surmodics Announces Launch of Serene® Single-Coat (SC) Solutions Offering Unmatched Lubricity & Durability to a Broader Rang...
October 31 2016 - 8:05AM
Business Wire
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical
device and in vitro diagnostic technologies to the healthcare
industry, announced the launch of a single-coat formulation of its
most advanced hydrophilic medical device coating, Serene®
solutions. Specifically formulated for individual medical device
applications, Serene Single-Coat (SC) solutions allow manufacturers
to leverage their legacy coating process to apply this surface
treatment.
Surmodics’ Serene coatings help device manufacturers meet the
challenge of achieving the right balance of lubricity (reduction in
friction) and durability for intravascular products. Surmodics
continues to lead the way with significant advances in coating
formulations, achieving low friction and low-particulate generation
with the latest formulation of Serene SC coating, that meet
manufacturer’s current processes to accelerate development and meet
customer needs.
“With regulatory attention increasingly focused on lowering
particulates, we’ve experienced quick adoption of Serene coatings
among manufacturers already equipped for a two-coat process,” said
Gary Maharaj, president and chief executive officer. “Serene SC
solutions will broaden the range of medical device companies able
to benefit from the unmatched lubricity and durability this product
family provides.”
Hydrophilic coatings continue to be a critical design input to
help medical devices navigate tortuous vascular pathways.
Hydrophilic coatings reduce risk of damage to blood vessel walls
and allow physicians to reach distal treatment sites for procedures
for improved therapeutic outcomes.
About Serene Coating Solutions
The Surmodics family of Serene hydrophilic coatings combine
unmatched lubricity and durability, including dramatically improved
particulate reduction. Serene hydrophilic coatings bond to a wide
variety of substrates and have a proven regulatory record with
leading coronary, peripheral, neurovascular and structural heart
devices.
Serene coatings are applied using Surmodics’ patented Photolink®
UV curing process, which covalently bonds surface treatments to
substrates at ambient temperature. This flexible technology can
easily be incorporated into existing manufacturing processes, and
can markedly reduce production time and reagent costs compared to
both thermal-curing and alternative light-activated processes.
About Surmodics, Inc.
Surmodics is the global leader in surface modification
technologies for intravascular medical devices and a leading
provider of chemical components for in vitro diagnostic (IVD) tests
and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the company is executing a key growth
strategy for its medical device business by expanding to offer
total intravascular product solutions to its medical device
customers. The combination of proprietary surface technologies,
along with enhanced device design, development and manufacturing
capabilities, enables Surmodics to significantly increase the value
it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements.
With this focus on offering total product solutions, Surmodics’
mission remains to improve the detection and treatment of disease
by using its technology to provide solutions to difficult medical
device and diagnostic challenges. Surmodics is headquartered in
Eden Prairie, Minnesota. For more information, visit
www.surmodics.com. The content of Surmodics’ website is not part of
this press release or part of any filings that the company makes
with the SEC.
Serene® is a registered trademark of Surmodics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161031005382/en/
Surmodics, Inc.Andy LaFrence, 952-500-7000Vice President of
Finance and Information Systems and Chief Financial Officer
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024